Abiopharma

🔍 Schoeneck James A (Director)

Company: Calidi Biotherapeutics, Inc. (CLDI)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Acquired 75,000 shares of Common Stock at $2.0 per share (Direct)
  Date: 2025-08-21 | Code: P | equity_swap_involved: 0 | shares_owned_after: 76,134.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: H | nature_of_ownership: Held with Spouse | shares_owned_after: 347.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: H | nature_of_ownership: By James & Cynthia Schoeneck Family Trust | shares_owned_after: 8,033.00 | Footnotes: F3
• Acquired 75,000 shares of Warrant (right to buy) at $2.0 per share (Derivative)
  Date: 2025-08-21 | Code: P | Expires: 2030-08-21 | Exercise: 2025-08-21 | equity_swap_involved: 0 | shares_owned_after: 75,000.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.
• F2: Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.
• F3: The reporting person is a trustee of the James & Cynthia Schoeneck Family Trust. As such, the reporting person may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the James & Cynthia Schoeneck Family Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shared for purposes of Section 16 or for any other purpose.
• REMARKS: Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated April 22, 2024).